Investigational drug group:Intravitreal injection of KSI-301 (5mg)

Canceled by the investigator A Prospective, Randomized, Double-Masked, Active Comparator-Controlled, Multi-Center, Two-Arm, Phase III Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-Naive Diabetic M

A Prospective, Randomized, Double-Masked, Active Comparator-Controlled, Multi-Center, Two-Arm, Phase III Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-Naive Macular Edema Secondary to Retinal Vein Occlusion (RVO)